Skip to main content

AI-based Clinical Trials Solution Provider Market Worth $5.2 Billion By 2028

Page 1

Global AI-based Clinical Trials Solution Provider Market Analysis, Size, Growth, Share, Trend, Outlook & Forecast to 2028

AI-based Clinical Trials Solution Provider Market Growth & Trends The global AI-based clinical trials solution provider market size is expected to reach USD 5.2 billion by 2028 and is expected to expand at a CAGR of 21.7% over the forecast period, according to a new report by Grand View Research, Inc. Rising adoption of AI-based platforms and technologies by pharmaceutical companies and academia, along with increasing adoption of artificial intelligence (AI) are among the factors driving the market growth. In addition, increasing public and private sector offerings for boosting the research and development in various therapeutic areas, coupled with diverse applications provided by AI in the field of clinical trials is further supporting the growth. Based on phase, the phase-II segment dominated the market with a share of 48.5% in 2020. This high share is attributable to a higher number of active interventional studies in the second phase. Furthermore, the second phase is crucial for analyzing the immediate outcome of the overall desired outcome from the completion of clinical trials. In addition, since improvements in the further phases of the trial and determination of measures with regards to AI-based tools can be effectively carried out in this phase, the segment comprises of higher revenue share. Download Exclusive Sample Report (118 Pages PDF with All Related Graphs & Charts) For Free @ https://www.grandviewresearch.com/industry-analysis/artificial-intelligencebased-clinical-trials-solution-provider-market

North America dominated the market and accounted for the largest revenue share of 43.6% in 2020 owing to various factors including a rising number of start-ups and AI in drug


development-based companies in the region, growing awareness and adoption of AI-based technologies, an increasing number of interventional studies. In addition, supportive government initiatives and growing strategic initiatives by major players are driving the demand for AI-based clinical trial solutions in the region. In addition, the COVID-19 pandemic has also led to a surge in the utilization of AI-based technologies. Increasing adoption of technologically advanced solutions for drug development and utilization of such solutions for analyzing the recruited patient’s data are some of the prominent factors contributing to the upsurge in adoption during the pandemic. Furthermore, the pandemic was also responsible for many clinical trials being put on hold and hence major companies shifted their focus on utilizing AI-based solutions, thereby boosting decentralized interventional studies. Moreover, a large amount of patient data analyzed and consolidated effectively through these solutions has further supported the market growth. For instance, according to a 2021 article published in Healthcare IT News, there is an increase in the adoption of AI-based clinical trial solutions for oncology during COVID-19. Therefore, such instances signify affirmative growth of the market, even during the pandemic. AI-based Clinical Trials Solution Provider Market Report Highlights 

The market is anticipated to witness significant growth by 2028 owing to various applications provided by AI in the field of clinical trials and the growing adoption of such platforms by pharmaceutical companies The phase-II trials segment dominated the market in 2020, owing to the increasing number of interventional studies active in this phase

The oncology segment dominated the market in 2020, owing to the rising prevalence of cancer and a growing number of interventional studies in the oncology field

The pharmaceutical companies segment accounted for the highest revenue share in 2020 owing to the increasing adoption of artificial intelligence technologies for drug development by major pharmaceutical players

North America dominated the market and accounted for the largest revenue share of 43.6% in 2020, owing to various factors including an increasing number of clinical trials in the region, growing adoption of artificial intelligence platforms and tools, rising number of start-ups and companies based on artificial intelligence in drug development and growing awareness regarding AI-based tools and technologies

For More Insights Get FREE Detailed Sample Report @

https://www.grandviewresearch.com/industry-analysis/artificial-intelligence-based-clinicaltrials-solution-provider-market/request/rs1


AI-based Clinical Trials Solution Provider Market Segmentation Grand View Research has segmented the global AI-based clinical trials solution provider market based on clinical trial phase, therapeutic application, end user, and region: AI-based Clinical Trials Solution Provider Clinical Trial Phase Outlook (Revenue, USD Million, 2016 - 2028)  Phase-I 

Phase-II

Phase-III

AI-based Clinical Trials Solution Provider Therapeutic Application Outlook (Revenue, USD Million, 2016 - 2028)  Oncology 

Cardiovascular Diseases

Neurological Diseases or Conditions

Metabolic Diseases

Infectious Diseases

Others

AI-based Clinical Trials Solution Provider End-user Outlook (Revenue, USD Million, 2016 - 2028)  Pharmaceutical Companies 

Academia

Others

AI-based Clinical Trials Solution Provider Regional Outlook (Revenue, USD Million, 2016 - 2028)  North America

o

U.S.

o

Canada

o

U.K.

o

Germany

o

Italy

o

France

o

Spain

Europe


o

Russia

o

Australia

o

China

o

Japan

o

South Korea

o

India

Asia Pacific

Latin America o

Mexico

o

Brazil

o

Argentina

Middle East & Africa o

South Africa

o

Saudi Arabia

o

UAE

List of Key Players of AI-based Clinical Trials Solution Provider Market  Unlearn.AI, Inc. 

Saama Technologies

Antidote Technologies, Inc.

Phesi

Deep 6 AI

Innoplexus

Mendel.ai

Intelligencia

Median Technologies

Symphony AI

BioAge Labs, Inc.

AiCure, LLC

CONSILX

DEEP LENS AI


Halo Health Systems

Pharmaseal

Ardigen

Trials.Ai

Koneksa Health

Euretos

BioSymetrics

Google- Verily

GNS Healthcare

IBM Watson

Exscientia

Complete Report is Available (Including Full TOC, List of Tables & Figures, Graphs, and Chart) https://www.grandviewresearch.com/inquiry/451554/ibb


Turn static files into dynamic content formats.

Create a flipbook
AI-based Clinical Trials Solution Provider Market Worth $5.2 Billion By 2028 by Grand View Research Research - Issuu